Evidence map›Paper›PMID 41193673›Full record

ArticleMolecular psychiatry2026

The 4-alkyl chain length of 2,5-dimethoxyamphetamines differentially affects in vitro serotonin receptor actions versus in vivo psychedelic-like effects.

Dino Luethi, Grant C Glatfelter, Eline Pottie, Francesca Sellitti, Alexander D Maitland, Nicholas R Gonzalez, Lindsay A Kryszak, Shelley N Jackson, Marius C Hoener, Christophe P Stove and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Dino Luethi *Psychopharmacology Research, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland. dino.luethi@unibas.ch.ORCID http://orcid.org/0000-0003-0874-4875
Grant C Glatfelter *Designer Drug Research Unit, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, US.
Eline PottieLaboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium.ORCID http://orcid.org/0000-0002-9077-4055
Francesca SellittiNeuropharmacology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.
Alexander D MaitlandDesigner Drug Research Unit, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, US.
Nicholas R GonzalezDesigner Drug Research Unit, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, US.
Lindsay A KryszakTranslational Analytical Core, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, US.ORCID http://orcid.org/0000-0002-1901-6024
Shelley N JacksonTranslational Analytical Core, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, US.
Marius C HoenerNeuroscience Research, pRED, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.ORCID http://orcid.org/0000-0001-6510-6250
Christophe P StoveLaboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium.ORCID http://orcid.org/0000-0001-7126-348X
Matthias E LiechtiPsychopharmacology Research, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland.ORCID http://orcid.org/0000-0002-1765-9659
Martin SmieškoComputational Pharmacy, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.ORCID http://orcid.org/0000-0003-2758-2680
Michael H BaumannDesigner Drug Research Unit, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, US.
Linda D SimmlerNeuropharmacology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.ORCID http://orcid.org/0000-0003-3512-4057
Deborah RudinPsychopharmacology Research, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland.ORCID http://orcid.org/0000-0003-3069-9732

Funding

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) P5R5PM_206796Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) TMSGI3_211261Universiteit Gent (UGent) BOF23/PDO/073U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA) DA000522-16
6 · The paper itself

Abstract

Various ring-substituted α-methylphenethylamines (i.e., amphetamines) produce psychedelic-like effects that are primarily mediated by activity at 5-hydroxytryptamine 2A (5-HT

Indexed as

HallucinogensAmphetaminesAnimalsDOM 2,5-Dimethoxy-4-MethylamphetamineDose-Response Relationship, DrugHumansMaleMiceMice, Inbred C57BLReceptor, Serotonin, 5-HT2AAmphetaminesDOM 2,5-Dimethoxy-4-MethylamphetamineHallucinogensReceptor, Serotonin, 5-HT2A

Identifiers

PMID41193673
PMCPMC12916490

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.